Impact of Omega 3 Fatty Acid Supplementation on Aromatase in Obese Subjects

• Status: Recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: Female

Summary

Assess the impact of dietary omega 3 free fatty acids and/or letrozole on obese, postmenopausal breast cancer patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Andrew Brenner; The University of Texas Health Science Center at San Antonio
• Treatments: Letrozole

Criteria

Inclusion Criteria:

• At least 18 years of age.

• Postmenopausal as confirmed in medical history

• Ability to understand the purposes and risks of the study and has signed a written informed consent form approved by the investigator's IRB (Institutional Review Board)/Ethics Committee.

• Estrogen receptor positive breast cancer. Body mass index of 30 or greater.

• Consented for tissue collection on CTRC (Cancer Therapy and Research Center) repository 07-32

Exclusion Criteria:

• Cachexia

• Active systemic illness (infection including viral illnesses such as Hepatitis and HIV)

• Chronic use of NSAIDs (nonsteroidal anti-inflammatory drugs) aspirin or omega-3 free fatty acid supplementation within the last 60 days (defined as greater than or equal to 7 consecutive days)

• Any NSAIDs aspirin or omega-3 free fatty acid supplementation within the last 14 days

• History of medical noncompliance

• Scheduled date of surgical resection that would limit the amount of time taking the intervention to less than 21 days